Ligeledes havde lamivudin- refraktoriske patienter, som opnåede HBV DNA < 104 log10 kopier/ ml ved PCR i Uge 24, en lavere forekomst af resistens end de patienter, der ikke opnåede denne HBV DNA (kumulativ sandsynlighed over 5 år på henholdsvis 17, 6% [n=50] versus 60, 5% [n=135]).
Also, lamivudine-refractory patients who achieved HBV DNA < 104 log10 copies/ ml by PCR at Week 24 had a lower rate of resistance than those who did not (5-year cumulative probability 17.6% [n=50] versus 60.5% [n=135], respectively).